A technique that improves survival in patients with pancreatic cancer
He pancreas cancer This oncological disease more often in Men. So far, he has had mostly poor prognosis and little scientific progress regarding possible treatment.
In Spain pancreas cancer This third cause of death malignant tumors due to high mortality, as it is difficult early diagnosis.
Read also
However, they are investigating technique improve survival patients with metastatic pancreatic cancer who have not yet received any treatment.
Find out what it consists of new therapeutic strategy who promises to control pancreas cancer in a satisfactory manner.
What is pancreatic cancer: symptoms
He pancreas It is located between the stomach and the spine. This vital organ performs two main functions in organism:
- Exocrine function: He pancreas Factory Jdigestive tract which participate in decomposition food into substances that the body can use.
- endocrine function: He pancreas synthesizes insulin And glucagontwo hormones that help regulate blood levels blood sugar content and interfere with the process of use and storage energy what the body gets from food.
Read also
He pancreas cancer This is a type of cancer that develops in the tissues of the pancreas. Smoke It is one of the most common risk factors for this type of cancer.
In that 95% of patientsHe pancreas cancer It begins in the exocrine cells of the pancreas.
What’s worrying is that during first phasesthe disease does not manifest itself symptoms.
Just in more advanced stages appear signsbut not very specific ones, such as fatigue, dark urine, light stools, jaundice, loss of appetite and weight.
What is pancreatic cancer: symptoms
A technique that improves survival in patients with pancreatic cancer
He international work presented by the doctor Teresa Macarulla, Oncologist at the Vall d’Hebron Hospital and Principal Investigator of the VHIO at the European Society of Medical Oncology Gastrointestinal Tumours Congress.
Study shows promising results for combination therapy chemotherapy new generation standard immunotherapy with a new drug, an antagonist CD40 receptoras a first-line treatment in patients with metastatic pancreatic cancer.
Read also
In the essay V. Phase 2 published in The Lancet Oncology, involved 57 patients with metastatic pancreatic cancer.
At the moment it’s new therapeutic strategy included in clinical trials, demonstrated positive results in the fight against the disease for a longer period.
This technique is used to treat patients with metastatic pancreatic cancer managed to improve the quality of life these patients and improve them survival.
Read also
Therapeutic benefits in patients with metastatic pancreatic cancer
technique consisted of prescribing to patients “first dose immunotherapy prepare the tumor medium and then repeat the series chemotherapyfirst, and then immunotherapy”, explains Dr. Makarulla.
In addition, the expert reported that “due to the synergy between both drugs, in which chemotherapy is preferable to immunotherapy and vice versa“Patients respond better to treatment.”.
In particular, the research team checked second stage of the studywhat does this technique achieve therapeutic benefits is important for patients with pancreas cancer:
-They reached speed objective answer 40%.
-Average response time 12.5 months.
-Mean overall survival 14.3 months.
In particular, this study shows results promising preliminary data because it technique allowed us to reduce the size tumor and duplicate yours control longer.
This “has an impact on survival patients who live longer and better the quality of life“concludes Dr. Makarulla.
However, an expansion of the research sample is expected to confirm these data. encouraging results for patients
This information in no way replaces a diagnosis or doctor’s prescription. It is important to consult a specialist when symptoms appear and never self-medicate.